News | September 14, 2012

IBA Molecular Introduces Centers for Innovation

September 14, 2012 — IBA Molecular North America Inc., a manufacturer and distributor of PET imaging tracers, has announced the introduction of its Centers for Innovation, two unique facilities designed for advanced radiopharmaceutical contract development and manufacturing. The centers are located in Totowa and Somerset, N.J.  Complementing these sites are IBA Molecular's production capabilities for isotopes such as I-124, F-18, Zr-89 and in the future, Cu-64 and Y-86. The centers are expected to play an important role in the development of a new generation of disease-specific tracers and companion theragnostics.

The primary site is a state-of-the-art radiopharmaceutical facility in Totowa, N.J. This fully equipped 8,500-square-foot research and development center is staffed by a team of accomplished professionals, including radiochemists, nuclear pharmacists, QC chemists and cyclotron engineers. The staff has expertise in radio-labeling, product development and industrialization of new tracers, technology transfer and GMP production of doses for clinical trials.  These attributes make the site an ideal destination for collaborative projects. With both large (mAbs, proteins, etc.) and small molecule radio-labeling expertise, the center can develop processes to support almost any new tracer, including those that utilize isotopes such as F-18, I-124 and Zr-89.  All of these endeavors are geared toward supporting human clinical trials of novel tracers.

These GMP-validated sites provide a broad range of capabilities, including:

  • Compounding of I-124 capsules for clinical use
  • Producing the highest purity I-124 available under a DMF for this radioisotope
  • Production of novel tracers integral to preclinical translational research
  • Scalable infrastructure and investigational products for all phases of clinical studies
  • Production of novel tracers integral to hybrid-probe development
  • A supporting resource or "think-tank" for development and industrialization
  • Scalable infrastructure capable of supporting solid targetry for research isotope production including Cu-64, Y-86 and other isotopes


"The molecular imaging industry needs an accelerant to drive innovation and new products. Our specialized knowledge and outstanding facilities in radiopharmaceutical development and manufacturing are at the disposal of our partners and will undoubtedly assist in bringing new products to the market faster," said Lee Karras, president of IBA Molecular North America Inc. "These Centers for Innovation will provide researchers, pharma and biotech companies with access to our unmatched expertise in small and large molecules, as well as our proven track record with the development of novel tracers.  Standing alongside these centers is IBA Molecular's global commercial network of nuclear pharmacies, which will be paramount to the successful launch of any new, commercialized tracer."

IBA Molecular has development and manufacturing partnerships with a number of pharmaceutical firms, including Wilex, Aposense and Piramal Imaging, as well as ongoing research collaborations with noted medical institutions throughout the U.S. and Europe.

For more information: www.iba-molecular.com

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init